Abstract:Background/Objective(s) Familial recurrence in multiple sclerosis (MS) has been vastly studied. Genetic and environmental factors have been identified. However, few studies have described this phenomenon in pediatric onset multiple sclerosis (POMS) and its impact on clinical and prognostic profile. Material(s) and Method(s) A single-center retrospective observational descriptive study was conducted in the pediatric neurology department at the national institute Mongi Ben Hmida of Neurology of Tunis including patients meeting the 2017 McDonald criteria for relapsing-remitting MS with an age at onset before 18 years and another affected family member (AFM) to the third degree or less. Highly-active MS (HAMS) was defined according to MENACTRIMS guidelines (2024). Multiple sclerosis severity scale (MSSS) was calculated in POMS patients and their AFM. Rapid progressors were defined by a MSSS ≥ 5 and slow progressors were defined by MSSS < 5. Their demographic, clinical, radiological and evolutionary data were collected and analyzed. Result(s) Nine patients were included. Sex-ratio was 0.13. Age at onset varied from seven to 17 years. Seven patients had HAMS. In these cases, aggressive MS was noted in five AFM. Both HAMS patients and their AFM were treated by interferons and then switched to Natalizumab or Fingolimod. Time to escalation was one to three years longer in POMS than in AFM. MSSS was similar between POMS patients and their AFM with variation less than 1 in all cases. Rapid progressors accounted for five POMS cases. All of them had a rapid progressor AFM. Conclusion(s) Our study demonstrated a similar phenotype between index cases and affected relatives. In fact, POMS patients with a HAMS phenotype had AFM with a similar disease presentation. These similarities plead for a genetic contribution to the risk of developing a HAMS. More genetic research using genome wide association studies and new generation sequencing are needed to identify factors involved in MS pathogenesis in these patients. Treatment strategies were similar in POMS patients and their AFM with a longer delay to escalation in the former group. This is due to absence of approval for most second line disease-modifying therapies for pediatric patients. Larger-scale studies of familial MS cases are needed to identify prognostic factors and develop adequate treatment strategies for these patients.

Pediatric multiple sclerosis: pathogenesis, clinical and radiological features, diagnosis and treatment

Childhood Multiple Sclerosis: Clinical Features and Recent Developments on Treatment Choices and Outcomes.

[Clinical Features and Management of Multiple Sclerosis in Children].

Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A Review

Pediatric multiple sclerosis: an integrated outlook at the interplay between genetics, environment and brain-gut dysbiosis

Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature

The clinical features and prognosis of multiple sclerosis in 33 pediatric cases

Clinical and MRI Features in Pediatric Multiple Sclerosis

International Pediatric MS Study Group Global Members Symposium report

Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada's population

A Comprehensive Review on Multiple Sclerosis

Characteristics of Children and Adolescents With Multiple Sclerosis

Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder.

Multiple sclerosis: clinical aspects

Multiple sclerosis: emerging epidemiological trends and redefining the clinical course

Towards Treating Multiple Sclerosis Progression

Parental Experiences in Pediatric Multiple Sclerosis: Insights from Quantitative Research

Multiple sclerosis in a 4-year-old boy: A case report and literature review

126. Familial Pediatric Onset Multiple Sclerosis: A Retrospective Single-Center Observational Study

Neuropsychological performances, quality of life, and psychological issues in pediatric onset multiple sclerosis: a narrative review

First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center